STRAGEN Follow Verify

www.stragen.ch
STRAGEN
Type	Private
Industry	Pharmaceutical specialties and consumer health
Founded	1990
Slogan	Products developed by doctors for doctors
Headquarters	Geneva, Switzerland
Key people	M. Jean-Luc Tetard, Stragen Group's CEO and Founder,, S. Jan TETARD Vice President
Number of employees	51-200

STRAGEN is an international, privately held healthcare company focused on the development, registration and worldwide distribution of innovative medicinal products, generics, orphan drugs and medical devices. It provides pharmacovigilance (post-marketing and clinical trials), clinical development and regulatory strategies services. The company is headquartered in Geneva, Switzerland, with a wide network of 10 worldwide affiliates, running operations in more than 60 countries and with approximately more than 150 employees.

History

• 1990

- Founded as a small API trading platform;

• 2004

- the Stragen UK, Established with its head office located in Reigate Surrey, Stragen UK, as part of the Stragen Group, for registering and distributing of Stragen own-label generic pharmaceutical products in the UK;

• 2005

- ChemGenex Pharmaceuticals (treatments for cancer, metabolic diseases, and depression) has licensed exclusive worldwide rights from Stragen Pharma SA to use its manufacturing process and related analogs in the development of Phase II anticancer therapeutic Ceflatonin;

• 2008

- ChemGenex Pharmaceuticals Limited announced that Mr. Jean-Luc Tétard, the President of the Stragen Group of companies, has joined the company’s Board of Directors effective immediately;

• 2011

- Institut Pasteur has entered into a research and licensing pact with Stragen to develop pain management drug Opiorphin.

- Gene Signal-Stragen Pharma distribution agreement for France with Stragen’s Lyon office;

• 2016

- After several years of development, the Urapidil Oral dossier has been approved in Germany, Slovakia, the Czech Republic, and Austria;

• 2017

- Launch Of Urapidil Oral By Stragen France;

• 2018

- New visual brand identity which has adopted a rich palette of stimulating colors which represent the different STRAGEN business units;

Products

STRAGEN expands its scope over 3 core activities:

• Consumer health.
• Selected & advanced generics.
• Original drugs.

STRAGEN develops and manages the manufacturing of parenteral drugs, such as antibiotics (including Penicillin) and highly potent cytostatic agents. The company also offers expertise in the development and production of topical products like gels and creams, complex low-concentration hormonal products, niche modified release drugs, conventional release solid dosage forms, and invests in the development up to proof of concept of patented new drugs addressing orphan diseases or unmet medical needs.

CONSUMER (WOMEN) HEALTH
PREGNANCY	FERTILITY	MENOPAUSE	SKIN & VENOUS DISORDERS	IMMUNE & METABOLIC DISORDERS	WEIGHT LOSS
PREGNOSEA	FERTISITOL	ESTROFREE-100®	ELACNIA	LEVIKER®	LURALEAN
IODACIF	ENDELLIA	MENOTROFY	DIOSMIN 95®	SNIZTOP®
ELLOVA®	GYNEVIA

GENERICS
GYNAECOLOGY	ANTI-INFECTIVES	ANTI-INFLAMMATORY	CARDIOLOGY	DERMATOLOGY	EPILEPSY	HEMORRHAGE	ONCOLOGY
ATOSIBAN	CEFEPIME	DICLOFENAC 1%	AMIODARONE	ADAPALENE 1%	LEVETIRACETAM	TRANEXAMIC ACID	CYPROTERONE ACETATE
CYPROTERONE ACETATE	CEFOTAXIME		MILRINONE				OXALIPLATIN
CYPROTERONE ACETATE / ETHINYLESTRADIOL	CEFTAZIDIME		URAPIDIL				PACLITAXEL
DESOGESTREL	CEFTRIAXONE		URAPIDIL ORAL
DESOGESTREL / ETHINYLESTRADIOL	CEFUROXIME
DIENOGEST / ETHINYLESTRADIOL	CLOXACILLIN
DROSPIRENONE / ETHINYLESTRADIOL	ERYTHROMYCIN
GESTODENE / ETHINYLESTRADIOL	FLUCLOXACILLIN
NOMEGESTROL ACETATE	PIPERACILLIN / TAZOBACTAM

PRODUCTS IN DEVELOPMENT - ORIGINAL DRUGS
ALX-009 - ALAXIA is an innovative First-in-Class orphan drug combination of two endogenous substances administered by inhalation. ALX-009 is addressing a strong unmet medical need, targeting multidrug-resistant (MDR) bacterial infections not treatable by current antibiotic therapies by contributing to the lung’s innate immune system response.	STR-324 is a First-in-Class non-opioid painkiller with a safe and non-addictive profile and innovative mode of action. Enkephalins are strong endogenous analgesic peptides that are quickly inactivated by peptidases NEP and APN. STR-324 is the synthetic equivalent of the natural human peptide inhibiting the degradation of enkephalin and thus amplifying their strong analgesic potential. Due to its unique mode of action, no opioid-like side effects are expected.

Services and therapeutic areas

STRAGEN offers tailored solutions for pharmacovigilance and clinical development strategies.

Pharmacovigilance	Scientific information	Medical affairs	Compassionate use
Pharmacovigilance (PV) system conception & implementation.	Coordination platform. Responses to scientific & medical requests.	Medical support for scientific advice meetings with agencies.	Coordination platform (documentation, logistics, records).
Qualified personnel for PV (QPPV & Deputy).		Consulting for clinical development programmes.
Full service Contract Safety Organization.

Therapeutic areas	Ginecology Epilepsy Phlebology Oncology Cardiology Anti-infectives Haemorrhage Anti-inflammatory Dermatology Immune and metabolic disorders Vascular disorders

Competition

The company’s competitors on the Chronic Myelogenous Leukemia Treatment Market, identified by the type of treatment (Symptomatic Treatment and Disease-Specific Treatment), Drug Type (Generic and Branded) and Test (Retail Pharmacies, Hospital Pharmacies and Specialty Pharmacies) are Pfizer Inc., Otsuka Pharmaceutical Co. Ltd., Bristol-Myers Squibb, Schering Plough, Stragen Pharma SA, Teva Pharmaceuticals Industries Ltd., Prism Pharmaceuticals, Bio-Path Holdings, Hoffman-La Roche Ltd., Incyte Corporation, Novartis AG and Hospira Inc.

Controversies

None

Top 5 Recent Tweets

Date	Author	Comment
March 20, 2023	oracion_001	One of my few overseas followers, StraGen(@SGen410 ), created a video featuring his OC Tapua and my OC Sheryl (in h… https://t.co/3uBMz5lqa6

Top 5 Recent News Headlines

1. 12-21-2018 - Chronic Myelogenous Leukemia Treatment Market SWOT analysis & Key Business Strategies by leading industry Players (Pfizer Inc., Otsuka Pharmaceutical Co. Ltd., Bristol-Myers Squibb, Schering Plough, Stragen Pharma SA) - The leading players in the market are Pfizer Inc., Otsuka Pharmaceutical Co. Ltd., Bristol-Myers Squibb, Schering Plough, Stragen Pharma SA, Teva Pharmaceuticals Industries Ltd., Prism Pharmaceuticals, Bio-Path Holdings, Hoffman-La Roche Ltd., Incyte Corporation, Novartis AG and Hospira Inc.. The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and market share of the overall industry.
2. 11-28-2018 - Leviker – Natural and innovative solution for fatty disorders of the liver - On 28.11.2018 in the auditorium of ZMC, Dr. Sasho Blazevski held a presentation titled “Leviker – Natural and innovative solution for fatty disorders of the liver”.
3. 02-14-2017 - A possible alternative to morphine – inspired by spit - The researchers at Institut Pasteur worked with a company, Stragen, to create a modified version of opiorphin called STR-324, designed to increase its stability. STR-324 should be able to be taken orally or intravenously, though so far only an injectable form is being tested. Neuropathic pain and other chronic pain syndromes are notoriously difficult to treat and are often resistant to conventional opioid drugs. If STR-324 is more effective for neuropathic pain that other opioids, it will be a significant new painkiller.

References

Top Authors

• Maria Jose Torres Rubio
• Ivana Pesic Topic
• View all authors

Verification history

• 1,903 days ago


• 1,903 days ago


• 2,074 days ago


• View all verifications